Grants and Contributions:
Title:
Synthesis and testing of glycan scaffolds (mono- and multi-valent forms) for evaluating glycan receptors of SARS-CoV-2
Agreement Number:
972122
Agreement Value:
$101,635.00
Agreement Date:
May 10, 2021 - Mar 31, 2022
Description:
For pathogens such as the SARS-CoV-2 virus that are spread through inhalation, the cells of the lung are the first line of defense for the host. A detailed understanding of the temporal and structural components of these interactions may be used to augment the host’s immune protection system. These components include the glycans and their receptors on both the host and the viral surface. It is anticipated that unravelling the interactions of the host’s glycans with viral receptors will allow for the development of practical diagnostic and therapeutic modalities. The SARS-CoV-2 virus utilizes its spike protein for attachment and internalization into host cells as a pivotal event required for viral replication. There is evidence that the first step of these events is the interaction of the N-terminal domain (NTD) of the spike protein with sialic acid-based receptors lining the respiratory tract. The aim of this Project is to identify key competitor glycans to the postulated SARS-CoV-2 virus glycan receptor that may also be useful for the development for both diagnostics and therapeutics.
Organization:
National Research Council Canada
Expected Results:
In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.
Location:
Ottawa, Ontario, CA K1A 0R6
Reference Number:
172-2021-2022-Q1-972122
Agreement Type:
Grant
Report Type:
Grants and Contributions
Recipient Business Number:
897184792
Recipient Type:
For-profit organization
Recipient's Legal Name:
Sussex Research Laboratories Inc
Federal Riding Name:
Ottawa–Vanier
Federal Riding Number:
35078
Program:
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Program Purpose:
Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.
NAICS Code:
541710 - R&D in the physical, engineering and life sciences